Friday, 14 November 2014 35 Re fer to last page for import ant disclosures. R e g i o n a l M o r n i n g N o t e s COMPANY UPDATE HOLD (Maintained) Share Price Bt135.00 Target Price Bt140.00 Upside +3.7% COMPANY DESCRIPTION One of the country's largest private hospitals in Bangkok with JCI accreditation and caters to both foreign and local patients. STOCK DATA GICS sector Health Care Bloomberg ticker: BH TB Shares issued (m): 728.6 Market cap (Btm): 98,361.1 Market cap (US$m): 2,997.9 3-mth avg daily t'over (US$m): 2.8 Price Perform ance (%) 52-week high/low Bt142.50/Bt82.00 1mth 3mth 6mth 1yr YTD 5.5 0.7 32.4 48.8 53.8 Major Shareholders % Sophonpanich family 30.7 Bangkok Dusit Medical Services 24.0 UOB Kay Hian (Hong Kong) 8.4 FY14 NAV/Share (Bt) 14.90 FY14 Net Cash/Share (Bt) 0.66 PRICE CHART 90 100 110 120 130 140 150 160 170 80 100 120 140 160 (%) (lcy) BUMRUNGRAD HOSPITAL PUB CO BUMRUNGRAD HOSPITAL PUB CO/SET INDEX 0 10 20 30 Nov 13 Jan 14 Mar 14 May 14 Jul 14 Sep 14 Nov 14 Volume (m) Source: Bloomberg ANA LYST Kowit Pongwinyoo +662 659 8304 [email protected]Bumr ungrad Hospit al (BH TB) Good News Priced In With the easing of politi cs, international patients have started to return to BH faster than expected. The trend is expected to continue and gather momentum next year. Coupled with expanded capacity and good operating margins, BH’s earnings growth should reach 22% next year. However, most of the good news has been priced in. Maintain HOLD. Target price: Bt140.00. Entry pric e: Bt120.00. WHAT’S NEW International patients have returned.After suffering from declining international patient volumes as a result of political conflicts in 1H14, Bumrungrad Hospital’s (BH) international patient volume has started coming back in 3Q14. This followed the easing political situation in Thailand after the military coup in May. In 3Q14, international patient volume increased 3% after a negative growth in the last two quarters. As we expect the political situation in Thailand to remain calm in the foreseeable future, we expect international patient volume to continue to improve. Leading the comeback are international patients from the Middle East. We therefore expect another good set of results in 4Q14 and into 2015. Initially, it seems the martial law was a major obstacle to the return of international patients. But the rising international patients at BH suggest they are ignoring the martial law and contine to seek treatment at BH. The return of international patients is crucial to BH’s overall performance as international revenue accounted for over 60% of its total revenue in the past two years. The revenue proportion from international patients was restored back to 61% in 9M14. Sufficient capacity at Sukhumvit campus until mid-18. After opening five floors in Bumrungrad International Clinic for outpatients in May l3, BH has just added 18 ICU beds and 58 ward beds, raising its licensed bed capacity to 580. At the moment, BH plans to develop a nearby building, Bumrungrad Tower (BH Residence). The company is studying whether to renovate the building for hospital usage or to house its back-office staff to reducing rental cost. Renovations may take one year. With all these developments, it will esnsure sufficient capacity at the Sukhumvit campus to service both Thai and international patients until mid-18 when the new hospital on New Pethburi Road will open for services.KEY FINANCIALS Year to 31 Dec (Bt m) 2012 2013 2014F 2015F 2016F Net turnover 12,982 14,346 15,484 17,913 20,306 EBITDA 3,160 3,871 4,232 4,999 5,749 Operating profit 2,445 2,983 3,210 3,905 4,522 Net profit (rep./act.) 2,558 2,521 2,679 3,254 3,749 Net profit (adj.) 1,698 2,370 2,625 3,200 3,695 EPS (Bt) 2.3 3.3 3.6 4.4 5.1 PE (x) 57.9 41.5 37.5 30.7 26.6 P/B (x) 11.6 10.2 9.1 7.8 7.0 EV/EBITDA (x) 31.0 25.3 23.1 19.6 17.0 Dividend yield (%) 1.3 1.4 1.5 1.7 1.9 Net margin (%) 19.7 17.6 17.3 18.2 18.5 Net debt/(cash) to equity (%) (8.2) (4.0) (4.4) (12.3) (13.4) Interest cover (x) 13.2 15.8 22.9 27.1 31.2 ROE (%) 33.6 27.8 26.2 27.7 30.0 Consensus net profit - - 2,739 3,228 3,722 UOBKH/Consensus (x) - - 0.96 0.99 0.99 Source: Bumrungrad Hospital, Bloomberg, UOB Kay Hian 1
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
8/10/2019 Bumrungrad Hospital PCL - Good News Priced In
International patients have returned. After suffering from declining international patient
volumes as a result of political conflicts in 1H14, Bumrungrad Hospital’s (BH) international
patient volume has started coming back in 3Q14. This followed the easing politicalsituation in Thailand after the military coup in May. In 3Q14, international patient volume
increased 3% after a negative growth in the last two quarters. As we expect the political
situation in Thailand to remain calm in the foreseeable future, we expect international
patient volume to continue to improve. Leading the comeback are international patients
from the Middle East. We therefore expect another good set of results in 4Q14 and into
2015. Initially, it seems the martial law was a major obstacle to the return of international
patients. But the rising international patients at BH suggest they are ignoring the martial
law and contine to seek treatment at BH. The return of international patients is crucial to
BH’s overall performance as international revenue accounted for over 60% of its total
revenue in the past two years. The revenue proportion from international patients was
restored back to 61% in 9M14.
Sufficient capacity at Sukhumvit campus until mid-18. After opening five floors in
Bumrungrad International Clinic for outpatients in May l3, BH has just added 18 ICU bedsand 58 ward beds, raising its licensed bed capacity to 580. At the moment, BH plans to
develop a nearby building, Bumrungrad Tower (BH Residence). The company is
studying whether to renovate the building for hospital usage or to house its back-office
staff to reducing rental cost. Renovations may take one year. With all these
developments, it will esnsure sufficient capacity at the Sukhumvit campus to service both
Thai and international patients until mid-18 when the new hospital on New Pethburi Road
will open for services.
KEY FINANCIALSYear to 31 Dec (Btm) 2012 2013 2014F 2015F 2016F
This report is prepared and/or distributed by UOB Kay Hian Pte Ltd (“UOBKH”), which is a holder of a capital markets services licence andan exempt financial adviser in Singapore.
This report is provided for information only and is not an offer or a solicitation to deal in securities or to enter into any legal relations, nor anadvice or a recommendation with respect to such securities.
This report is prepared for general circulation. It does not have regard to the specific investment objectives, financial situation and the
particular needs of any recipient hereof. Advice should be sought from a financial adviser regarding the suitability of the investmentproduct, taking into account the specific investment objectives, financial situation or particular needs of any person in receipt of therecommendation, before the person makes a commitment to purchase the investment product.
This report is confidential. This report may not be published, circulated, reproduced or distributed in whole or in part by any recipient of thisreport to any other person without the prior written consent of UOBKH. This report is not intended for distribution, publication to or use byany person in any jurisdiction outside Singapore or any other jurisdiction as UOBKH may determine in its absolute discretion, where thedistribution, publication or use of this report would be contrary to applicable law or would subject UOBKH and its connected persons (asdefined in the Financial Advisers Act, Chapter 110 of Singapore) to any registration, licensing or other requirements within such jurisdiction.
The information or views in the report (“Information”) has been obtained or derived from sources believed by UOBKH to be reliable.However, UOBKH makes no representation as to the accuracy or completeness of such sources or the Information and UOBKH acceptsno liability whatsoever for any loss or damage arising from the use of or reliance on the Information. UOBKH and its connected personsmay have issued other reports expressing views different from the Information and all views expressed in all reports of UOBKH and itsconnected persons are subject to change without notice. UOBKH reserves the right to act upon or use the Information at any time,including before its publication herein.
Except as otherwise indicated below, (1) UOBKH, its connected persons and its officers, employees and representatives may, to theextent permitted by law, transact with, perform or provide broking, underwriting, corporate finance-related or other services for or solicitbusiness from, the subject corporation(s) referred to in this report; (2) UOBKH, its connected persons and its officers, employees and
representatives may also, to the extent permitted by law, transact with, perform or provide broking or other services for or solicit businessfrom, other persons in respect of dealings in the securities referred to in this report or other investments related thereto; (3) the officers,employees and representatives of UOBKH may also serve on the board of directors or in trustee positions with the subject corporation(s)referred to in this report. (All of the foregoing is hereafter referred to as the “Subject Business”); and (4) UOBKH may otherwise have aninterest (including a proprietary interest) in the subject corporation(s) referred to in this report.
As of the date of this report, no analyst responsible for any of the content in this report has any proprietary position or material interest inthe securities of the corporation(s) which are referred to in the content they respectively author or are otherwise responsible for.
Each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this report in any eventaccurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was producedindependently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of theSubject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and willnot receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or to
any sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, thecompensation received by each such research analyst is based upon various factors, including UOBKH’s total revenues, a portion ofwhich are generated from UOBKH’s business of dealing in securities.
IMPORTANT DISCLOSURES FOR INCLUDED RESEARCH ANALYSES OR REPORTS OF FOREIGN RESEARCH HOUSES
Where the report is distributed in Singapore and contains research analyses or reports from a foreign research house, please note:
(i) recipients of the analyses or reports are to contact UOBKH (and not the relevant foreign research house) in Singapore in respect of anymatters arising from, or in connection with, the analysis or report; and(ii) to the extent that the analyses or reports are delivered to and intended to be received by any person in Singapore who is not anaccredited investor, expert investor or institutional investor, UOBKH accepts legal responsibility for the contents of the analyses or reports
IMPORTANT DISCLOSURES FOR U.S. PERSONS
This research report was prepared by UOBKH, a company authorized, as noted above, to engage in securities activities in Singapore.UOBKH is not a registered broker-dealer in the United States and, therefore, is not subject to U.S. rules regarding the preparation ofresearch reports and the independence of research analysts. This research report is provided for distribution by UOBKH (whether directlyor through its US registered broker dealer affiliate named below) to “major U.S. institutional investors” in reliance on the exemption fromregistration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the “Exchange Act”). All US persons that
44
8/10/2019 Bumrungrad Hospital PCL - Good News Priced In
receive this document by way of distribution from or which they regard as being from UOBKH by their acceptance thereof represent andagree that they are a major institutional investor and understand the risks involved in executing transactions in securities.
Any U.S. recipient of this research report wishing to effect any transaction to buy or sell securities or related financial instruments based onthe information provided in this research report should do so only through UOB Kay Hian (U.S.) Inc (“UOBKHUS”), a registered broker-dealer in the United States. Under no circumstances should any recipient of this research report effect any transaction to buy or sellsecurities or related financial instruments through UOBKH.
UOBKHUS accepts responsibility for the contents of this research report, subject to the terms set out below, to the extent that it isdelivered to and intended to be received by a U.S. person other than a major U.S. institutional investor.
The analyst whose name appears in this research report is not registered or qualified as a research analyst with the Financial IndustryRegulatory Authority (“FINRA”) and may not be an associated person of UOBKHUS and, therefore, may not be subject to applicablerestrictions under FINRA Rules on communications with a subject company, public appearances and trading securities held by a researchanalyst account.
Analyst Cert if ication/Regu lat ion AC
As noted above, each research analyst of UOBKH who produced this report hereby certifies that (1) the views expressed in this reportaccurately reflect his/her personal views about all of the subject corporation(s) and securities in this report; (2) the report was producedindependently by him/her; (3) he/she does not carry out, whether for himself/herself or on behalf of UOBKH or any other person, any of theSubject Business involving any of the subject corporation(s) or securities referred to in this report; and (4) he/she has not received and willnot receive any compensation that is directly or indirectly related or linked to the recommendations or views expressed in this report or toany sales, trading, dealing or corporate finance advisory services or transaction in respect of the securities in this report. However, thecompensation received by each such research analyst is based upon various factors, including UOBKH’s total revenues, a portion ofwhich are generated from UOBKH’s business of dealing in securities.
Copyright 2014, UOB Kay Hian Pte Ltd. All rights reserved.